Glial Restricted Neural Progenitor Cell Production for Rett Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Rett Syndrome, a neurological disorder caused by mutations in the MECP2 gene, are ineffective, and the challenge lies in rescuing mutant neurons through transplantation of healthy astrocytes, which is hindered by the sensitivity and difficulty in producing large numbers of differentiated astrocytes.
Innovation Solution
A method for generating glial restricted neural progenitor cells (GRNPCs) by culturing embryonic stem cells or induced pluripotent stem cells in specific media conditions, allowing for the expansion of these cells in large quantities and their subsequent differentiation into astrocytes, which can be used to treat neurological disorders by transplanting them into neural tissue.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If differentiated human astrocytes are used for transplantation, then therapeutic efficacy is improved, but production difficulty and sensitivity to stressors worsen
Solution Approach 1:
The patent segments the astrocyte production process into distinct stages: generating neural progenitor cells from ESCs/iPSCs, expanding them in suspension culture to form aggregates, and then differentiating into astrocytes. This segmentation allows each stage to be optimized independently, improving both production ease and therapeutic efficacy.
Solution Approach 2:
The patent performs preliminary expansion of neural progenitor cells in suspension culture before differentiation. This preliminary action creates a large pool of progenitor cells that can then be differentiated into astrocytes, overcoming the limitation of being able to produce only small numbers of differentiated astrocytes directly.
2Quantity of substance
If large numbers of differentiated astrocytes are produced, then transplantation efficacy is improved, but cell sensitivity to cultivation stressors worsens
Solution Approach 1:
The patent separates the production process into two phases: expanding neural progenitor cells in suspension (which are more robust) and then differentiating into astrocytes. This allows large numbers of cells to be produced at the progenitor stage without exposing differentiated astrocytes to prolonged cultivation stressors.
Solution Approach 2:
The patent uses neural progenitor cells as an intermediary population between ESCs/iPSCs and mature astrocytes. These progenitor cells can be expanded in large numbers and then differentiated into astrocytes, acting as a buffer that protects against stressors affecting differentiated cells during expansion.
3Productivity
If neural progenitor cells are expanded in suspension culture, then production scalability is improved, but process complexity worsens
Solution Approach 1:
The patent employs dynamic suspension culture conditions with controlled agitation and aeration that can be scaled from small to large volumes. The process transitions from static adhesion culture to dynamic suspension culture, enabling scalability while maintaining cell health through optimized physical parameters.
Data Source
AI summary
The disclosure is directed to a method to generate glial restricted neural progenitor cells (GRNPCs), and uses thereof, including for the treatment of neurological or neurodegenerative disorders.